A vaccine study for women
Healthy women from 16 to 35 years of age who regularly spend time with young children are invited to see if they qualify. Merck V160-002is a study to evaluate the safety and effectiveness of the V160-002 cytomegalovirus (CMV) vaccine.
About Cytomegalovirus (CMV)
CMV is a virus in the same family as the herpes virus that is present in a large portion of the population. CMV is spread by direct contact with body fluids, such as saliva, blood, urine, tears, etc.
Most CMV infections are “silent,” meaning most people who are infected with CMV exhibit no signs or symptoms. However, CMV can cause serious disease in newborns when a mother is infected during pregnancy – this is known as congenital CMV infection. CMV is the leading cause of non-genetic childhood hearing loss. It is estimated that every hour, one child is permanently disabled by CMV, and scientific research has found a connection between CMV and miscarriage.
Interested in participating? Please fill out the following form and we will contact you.